UROCAM

UROCAM was a Canadian medical device company focused on diagnostic and treatment technologies in urology and oncology. Available public descriptions indicate the company developed proprietary technology called UPRCOM for prostate cancer applications, using nuclear imaging and real-time tissue-response monitoring during ablation to adjust radiofrequency delivery and reduce overheating. The company also announced Health Canada approval in 2020 for distribution of the GeneFinder COVID-19 test kit in Canada. Third-party company databases describe UROCAM as founded in 2017 in Vaughan, Ontario, and later becoming inactive or "deadpooled." Public information on commercial traction, financing, and an active operating business appears limited.